Irish drugs developer, Merrion Pharmaceuticals, today said that it their new state of the art facility in Citywest has been licensed under the EU Clinical Directive for Investigational medicinal products.

The license was granted by the Irish Medicines Board (IMB).

Merrion acquired the 30,000 sq.ft facility in July 2009. The facility is designed to most efficiently (lowest risk, fastest development) develop new drug products and manufacture for clinical development.

'The granting of this license is another important milestone for Merrion, as it allows us to manufacture for clinical trials," said John Lynch CEO Merrion Pharmaceuticals. "We have a great track record of high quality standards in rapidly developing and manufacturing products based on our GIPET technology. The IMB license for our Citywest facility will allow us to expand the number of products we can develop for ourselves and for partners."